Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04129125 · ClinicalTrials.gov registry record · NA

The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

A NA study, sponsored by Imperative Care.

Completed
Registry status
NA
Development phase
328
Enrollment target

NCT04129125: Completed NA study, sponsored by Imperative Care.

NCT04129125 is a NA study that has completed, run by Imperative Care. The registered enrollment target is 328 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04129125, a NA study, has completed, sponsored by Imperative Care.

COMPLETED
Registry status
NA
Development phase
328 participants
Enrollment target

Study Summary

The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well.

Primary Outcome

Reperfusion success was defined as achieving a modified Treatment in Cerebral Infarction (mTICI) score of ≥2b within three or fewer passes using the study device and without rescue therapy (e.g., additional thrombectomy devices or intra-arterial lytics). The mTICI scale ranges from 0 to 3, with higher scores indicating better reperfusion: 0 = no perfusion, 1 = minimal perfusion, 2a = partial (\<50%), 2b = substantial (≥50%), 2c = near complete, 3 = complete. This measure reports the number of pa

Interventions

  • DEVICE Zoom Reperfusion System

Trial Details

FieldValue
Enrollment Target 328 participants
Start Date 2021-10-01
Est. Completion 2024-05-28
Phase NA
Imperative Care

4 total trials

What the finished NCT04129125 record still lists

NCT04129125 is an interventional study that assigns participants to a tested intervention. The registered 328 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).

The record links to 0 conditions, and to 1 intervention - of which Zoom Reperfusion System is the first listed.

NCT04129125 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04129125 about?

NCT04129125 is a clinical study titled "The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System". The trial is designed to assess the safety and efficacy of using the Zoom Reperfusion System in subjects diagnosed with acute ischemic stroke and undergoing a thrombectomy procedure within 8 hours of last known well.

What is the current status of trial NCT04129125?

This trial is currently completed. It is a NA study. The enrollment target is 328 participants. The study started on 2021-10-01. Estimated completion is 2024-05-28.

What interventions are being tested in trial NCT04129125?

The interventions under investigation include: Zoom Reperfusion System (DEVICE).

Who is sponsoring clinical trial NCT04129125?

This trial is sponsored by Imperative Care, which has 4 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT04129125's enrollment target sits among peer trials

328 308th of 2000 higher than 1,692 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05156983 · 328 participants · Phase 3

    A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

  • NCT05380401 · 328 participants · NA

    Metabolic Mechanisms Induced by Enteral DHA and ARA Supplementation in Preterm Infants

  • NCT05548413 · 328 participants · NA

    Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

  • NCT06393725 · 328 participants · NA

    Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04129125, the US trial registry maintained by the National Library of Medicine. NCT04129125 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.